Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
European Heart Journal|September 4, 2014
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillationRiccardo Cappato, Michael D Ezekowitz, Allan L Klein, et al.
American Heart Journal|April 29, 2014
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversionMichael D Ezekowitz, Riccardo Cappato, Allan L Klein, et al.
The American Journal of Medicine|July 16, 2019
Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AFFreek W A Verheugt, Giuseppe Ambrosio, Dan Atar, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|December 19, 2019
Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registryWerner Hacke, Jean-Pierre Bassand, Saverio Virdone, et al.
Plos One|May 25, 2013
Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registryAjay K Kakkar, Iris Mueller, Jean-Pierre Bassand, et al.
JACC. Cardiovascular Interventions|March 19, 2018
Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI TrialMathieu Kerneis, C Michael Gibson, Gerald Chi, et al.
Plos One|January 26, 2018
Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillationJean-Pierre Bassand, Gabriele Accetta, Wael Al Mahmeed, et al.
Blood Advances|February 19, 2021
Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registryJean-Pierre Bassand, Saverio Virdone, Marc Badoz, et al.
Circulation|November 25, 2016
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment StrategyC Michael Gibson, Duane S Pinto, Gerald Chi, et al.
Circulation|December 28, 2018
Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial FibrillationJean-Pierre Bassand, Saverio Virdone, Samuel Z Goldhaber, et al.
Pageof 6